Biogen (BIIB) has been under focus owing to several key developments and movements. The firm's stock has shown a marginal increase of 1.1% since the last earnings report. Organizations such as Victory Capital Management and Erste Asset Management GmbH have cut their stake, whereas Zurcher Kantonalbank, Daiwa Securities, and Amundi have raised their holdings. Biogen has initiated
Felzartamab Phase III study for treating AMR in kidney transplants and has also seen
FDA acceptance for its Alzheimer’s drug,
LEQEMBI®. However, analysts have negative outlooks for its Q1 earnings. News of insider selling has been balanced against a proposed
acquisition of Sage Therapeutics and successful trials for treatments like Nusinersen for SMA. Biogen's bid to buy remaining stakes in Sage Therapeutics has been rejected. The firm's Alzheimer's medicine cleared a critical EU obstacle after a safety review. Finally, Biogen's financial predictions for 2025 show a decline despite a strong Q4.
Biogen BIIB News Analytics from Wed, 22 May 2024 07:00:00 GMT to Sat, 15 Mar 2025 22:38:46 GMT -
Rating 2
- Innovation -3
- Information 6
- Rumor 4
